Value of PAM50 risk of recurrence score in patients with HR positive HER2 negative early breast cancer and intermediate risk: A single cancer center institution prospective observational study

被引：0
|
作者：
Nicolai, Vincent [1 ]
Gilhodes, Julia [1 ]
Lacaze, Jean Louis [1 ]
Ung, Mony [1 ]
De Maio, Eleonora [1 ]
Duprez-Paumier, Raphaelle [1 ]
Vaysse, Charlotte [1 ]
Filleron, Thomas [1 ]
Jouve, Eva [1 ]
Selmes, Gabrielles [1 ]
Franchet, Camille [1 ]
Massabeau, Carole [1 ]
Chira, Cyprian [1 ]
Izar, Francoise [1 ]
Roche, Henri [1 ]
Pradines, Anne [1 ]
Dalenc, Florence [1 ]
机构：
[1] IUCT O, Toulouse, France
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-P2-18-06
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-18-06
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study
    Guerrero-Zotano, A.
    Perez-Garcia, J. M.
    Ruiz-Borrego, M.
    Bermejo, B.
    Gil-Gil, M.
    de la Haba, J.
    Conejo, E. Alba
    Quiroga, V
    Caranana, V
    Urruticoechea, A.
    Morales, S.
    Bellet, M.
    Anton, A.
    Fernandez-Abad, M.
    Sanchez-Rovira, P.
    Calabuig, L.
    Perez-Escuredo, J.
    Sampayo-Cordero, M.
    Cortes, J.
    Llombart-Cussac, A.
    ESMO OPEN, 2024, 9 (10)
  • [32] Agreement in Risk Prediction Between the 21-Gene Recurrence Score Assay (Oncotype DX®) and the PAM50 Breast Cancer Intrinsic Classifier™ in Early-Stage Estrogen Receptor-Positive Breast Cancer
    Kelly, Catherine M.
    Bernard, Philip S.
    Krishnamurthy, Savitri
    Wang, Bailiang
    Ebbert, Mark T. W.
    Bastien, Roy R. L.
    Boucher, Kenneth M.
    Young, Elliana
    Iwamoto, Takayuki
    Pusztai, Lajos
    ONCOLOGIST, 2012, 17 (04): : 492 - 498
  • [33] Change in treatment decisions according to Oncotype Dx Recurrence Score in node positive and negative, estrogen-receptor positive (ER+), HER2 negative breast cancer in a single institution
    Gasol Cudos, A.
    Morales Murillo, S.
    Panades Siurana, M. J.
    Vilardell Villellas, F.
    Canosa Morales, C.
    Mele Olive, J.
    Iglesias Martinez, E.
    Salud Salvia, A.
    BREAST, 2017, 32 : S92 - S93
  • [34] A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse
    Prat, Aleix
    Lluch, Ana
    Turnbull, Arran K.
    Dunbier, Anita K.
    Calvo, Lourdes
    Albanell, Joan
    de la Haba-Rodriguez, Juan
    Arcusa, Angels
    Ignacio Chacon, Jose
    Sanchez-Rovira, Pedro
    Plazaola, Arrate
    Munoz, Montserrat
    Pare, Laia
    Parker, Joel S.
    Ribelles, Nuria
    Jimenez, Begona
    Bin Aiderus, Abdul Aziz
    Caballero, Rosalia
    Adamo, Barbara
    Dowsett, Mitch
    Carrasco, Eva
    Martin, Miguel
    Dixon, J. Michael
    Perou, Charles M.
    Alba, Emilio
    CLINICAL CANCER RESEARCH, 2017, 23 (12) : 3035 - 3044
  • [35] The 21-gene recurrence score and chemotherapy use in triple negative breast cancer (TNBC) and HER2 positive breast cancer: A National Cancer Database study
    Boughey, J. C.
    Hoskin, T. L.
    Cocco, D.
    Day, C. N.
    Leon-Ferre, R.
    Habermann, E. B.
    Goetz, M. P.
    CANCER RESEARCH, 2019, 79 (04)
  • [36] Comparison of PAM50 risk of recurrence (ROR) scores with EndoPredict for predicting risk of distant metastasis in ER+/HER2-, early node-positive breast cancer patients treated with adjuvant chemotherapy - A GEICAM/ 9906 sub-study
    Martin, M.
    Brase, J. C.
    Perou, C. M.
    Ruiz, A.
    Prat, A.
    Weber, K. E.
    Calvo, L.
    Petry, C.
    Bernard, P. S.
    Ruiz-Borrego, M.
    Kronenwett, R.
    Santaballa, A. M.
    Rodriguez, C. A.
    Alvarez, I. M.
    Segui, M. A.
    Casas, M.
    Carrasco, E.
    Caballero, R.
    Rodriguez-Lescure, A.
    CANCER RESEARCH, 2013, 73
  • [37] Utility of oncotype in premenopausal women with hormonal receptor (hr) positive her2 negative early breast cancer
    Cudos, A. Gasol
    Murillo, S. Morales
    Der-Abrain, N. Tuset
    Guzman, D. R. Sanchez
    Villellas, F. Vilardell
    Orillo, E. Morera M.
    Morales, C. Canosa
    Olive, J. Mele
    Cid, L. Arbones
    BREAST, 2023, 68 : S19 - S19
  • [38] CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer
    Di Cosimo, Serena
    Porcu, Luca
    Cardoso, Fatima
    BREAST, 2021, 55 : 75 - 78
  • [39] A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast Cancer
    Prat, Aleix
    Tsai, Yi-Hsuan
    Pascual, Tomas
    Pare, Laia
    Adamo, Barbara
    Vidal, Maria
    Braso-Maristany, Fara
    Galvan, Patricia
    Brase, Jan Christoph
    Rodrik-Outmezguine, Vanessa
    Johnston, Stephen
    Ciruelos, Eva
    Parker, Joel S.
    CLINICAL CANCER RESEARCH, 2020, 26 (23) : 6141 - 6148
  • [40] Caveolin-1 gene expression provides additional prognostic information combined with PAM50 risk of recurrence (ROR) score in breast cancer
    Godina, Christopher
    Belting, Mattias
    Vallon-Christersson, Johan
    Isaksson, Karolin
    Bosch, Ana
    Jernstrom, Helena
    SCIENTIFIC REPORTS, 2024, 14 (01)
12345